NICE OK for Bravtovi skin cancer drug
The National Institute for Health and Care Excellence (NICE) has recommended Pierre Fabre’s Bravtovi and Mektovi combination as an option for some people with melanoma.
18th January 2019
Latest news
Janssen to use Apple watch for AFib
Johnson & Johnson’s Janssen has announced a research study using the Apple watch to help improve atrial fibrillation (AFib) outcomes, including stroke prevention, intending to to collaborate with Apple to assess the impact of the wearable technology on earlier detection of AFib, improved diagnosis and patient outcomes.
18th January 2019
Positive results for UB-311 Alzheimer's vaccine
United Neuroscience has announced a positive top-line results from the Phase IIa clinical study of UB-311 vaccine in patients with Alzheimer's disease.
18th January 2019
Venetoclax gets NICE approval for chronic lymphocytic leukaemia
The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Venclyxto to benefit thousands of adults with chronic lymphocytic leukaemia.
18th January 2019
Novartis and Uni of Oxford to join forces and use AI for diseases and drug development
Novartis and the University of Oxford’s Big Data Institute have announced that they are to establish a five-year research alliance using artificial intelligence to understand complex diseases and improve drug development.
18th January 2019
Immune cell clues offer hope to hypertension patients
Researchers led by the University of Edinburgh have pinpointed cells in the immune system that could be key to tackling high blood pressure.
18th January 2019
PharmaTimes CROY 2019 - deadline extended
It’s not too late! The deadline for the PharmaTimes Clinical Researcher of the Year (CROY) 2019 awards has been extended to the February 25.
17th January 2019
NICE approval for Verzenios in metastatic breast cancer
The National Institute for Health and Care Excellence has recommended Eli Lilly’s Verzenios in combination with an aromatase inhibitor as treatment option for locally advanced or metastatic breast cancer
17th January 2019
EU licence granted for Erleada in prostate cancer
Janssen’s new treatment for prostate cancer Erleada has been licensed by the European Commission.
17th January 2019
Scholl and COP announce partnership
Footcare brand Scholl has announced it is joining forces with The College of Podiatry (COP) to raise awareness of foot health.
17th January 2019
‘Innovative’ new disease and infection test
Queen’s University researchers have developed a new test to detect disease and infection that could save time, money and possibly lives.
17th January 2019
NICE endorsement means more donor livers could be used for transplantation
The National Institute for Health and Care Excellence has announced that an “exciting development” could increase the number of livers which can be safely used for transplantation.
16th January 2019
New breast cancer testing tool in development
A study carried out by researchers from the University of Cambridge, National Cancer Institute, National Institutes of Health in the US among others has shown how putting different genetic and risk factor data into a prediction equation could help us understand how likely a woman is to develop breast cancer.
16th January 2019
GSK extends expiration date for Tesaro offer
GlaxoSmithKline subsidiary Adriatic Acquisition Corporation (AAC) has extended the expiration date for its tender offer for US-based Tesaro.
16th January 2019
Pharma comments on Brexit withdrawal rejection
Pharmaceutical groups weigh in on the UK parliament’s rejection of the Brexit withdrawal agreement.
16th January 2019
